Abstract:e16561 Background: Cryotherapy is a prevalent percutaneous ablative therapy for solid tumors. However, studies on the clinical practice of endoscopic cryotherapy for intraluminal malignancies are lacking. We aim to explore the feasibility of endoscopic cryotherapy for bladder cancer. Methods: In this multicenter, randomized, parallel controlled, non-inferiority trial, we compared endoscopic balloon cryoablation (EBCA) with a single instillation (SI) of pirarubicin after transurethral resection (TUR).Men or women aged 18-85 years with a clinical diagnosis of bladder cancer (tumor number no more than 3 and maximal tumor size no more than 3 cm) were included. The exclusion criteria were as follows: locally advanced urinary bladder cancer (clinical stage T3 or T4), lymph node involvement (N1) or distant metastasis (M1), severe organ dysfunction, severe coagulation disorder, sepsis, concomitant neoplastic malignancy and other conditions unsuitable for surgery or intravesical chemotherapy. Women in pregnancy or lactation were also excluded. Eligible participants were randomly assigned (1:1) to the TUR-EBCA or TUR-SI group. The primary endpoint was the residual-free rate at repeated TUR. A non-inferiority test was used to compare the primary endpoint with a chosen margin of 10%. The secondary endpoints included the recurrence-free survival (RFS), progression-free survival (PFS) and adverse events. Results: We recruited 227 participants between November, 2017, and September, 2020. In total, 205 patients received EBCA or SI after TUR, of whom 163 completed all the required interventions and follow-up. In the per-protocol analyses, 75 (91.5%) of 82 patients had no residual tumor in the TUR-EBCA group compared with 61 (76.5%) of 81 in the TUR-SI group (risk difference 14.9%; 95% confidence interval [CI] 0.03 to 0.27, P < 0.001), meeting the criteria for non-inferiority. Similar results were found in the after intention-to-treat analysis. After a median follow-up of 21 months, the TUR-EBCA group had better RFS(HR = 0.49; 95% confidence interval [CI] 0.24 to 0.99; Log-rank P = 0.046) and PFS (HR = 0.25; 95% confidence interval [CI] 0.08 to 0.77; Log-rank P = 0.0092). There were no significant differences in the SAEs rate (3.0% vs. 3.9%, p = 0.52). Conclusions: EBCA is a safe and effective adjuvant alternative to TUR for bladder cancer with the potential advantage of “energetically resecting” the tumor base. Clinical trial information: NCT02760953.

Endoscopic balloon cryoablation plus transurethral resection for bladder cancer: A phase 2, multicenter, randomized, controlled trial

Endoscopic Balloon Cryoablation Against Single Instillation after Transurethral Resection of Bladder Cancer: A Multicenter, Randomized, Controlled Noninferiority Trial.

TECIC bladder-sparing strategy for high-risk bladder cancer: Exploration and interim analysis of a multicenter, prospective, parallel controlled study (HSCRYO-104).

The Feasibility and Safety of Cryoablation As an Adjuvant Therapy with Transurethral Resection of Bladder Tumor: A Pilot Study.

Efficacy and Safety of Transurethral Resection of Bladder Tumour Combined with Chemotherapy and Immunotherapy in Bladder-Sparing Therapy in Patients with T1 High-Grade or T2 Bladder Cancer: a Protocol for a Randomized Controlled Trial.

Transurethral Electric Resection Plus Arterial Catheterization Chemotherapy for T2a Bladder Carcinoma

Endoscopic Cryoablation Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma

An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial

Evaluation of a New Cystoscopic Cryocatheter and Method for the In Situ Destruction of Bladder Cancer: Preliminary In vivo Study

A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer

The safety and efficacy of bladder cryoablation in a beagle model by using a novel balloon cryoprobe

Thulium laser en bloc resection of bladder tumor combined with intravesical instillation for the treatment of non-muscle-invasive bladder cancer

Use of in vivo Raman spectroscopy and cryoablation for diagnosis and treatment of bladder cancer

Cryoablation Inhibits the Recurrence and Progression of Bladder Cancer by Enhancing Tumour-Specific Immunity.

The clinical study of en bloc transurethral resection with 980 nm laser for treatment of primary non -muscle invasive bladder cancer

Transurethral Endoscopic Submucosal En Bloc Dissection for Nonmuscle Invasive Bladder Cancer: A Comparison Study of HybridKnife-assisted Versus Conventional Dissection Technique.

Ultrasound-guided cryoablation of early breast cancer: safety, technical efficacy, patients' satisfaction, and outcome prediction with MRI/CEM: a pilot case-control study

Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.

Two Micrometer Continuous-Wave Thulium Laser Treating Primary Non-Muscle-Invasive Bladder Cancer: Is It Feasible? A Randomized Prospective Study

Cryoablation for nonmetastatic castration resistant prostate cancer: feasibility, safety, quality of life and oncological outcomes

A retrospective comparison of thulium laser en bloc resection of bladder tumor and plasmakinetic transurethral resection of bladder tumor in primary non-muscle invasive bladder cancer